NUR 601 Module 7 Milestone Two Example

Milestone Two: The Trade-Off in the Bones, Phosphate, FGF23 and Secondary Hyperparathyroidism in a 58-Year-Old Man on Dialysis

[Student Name]

Southern New Hampshire University

NUR 601: Advanced Pathophysiology

Milestone Two

[Instructor Name]

[Date]

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

Milestone Two: The Trade-Off in the Bones, Phosphate, FGF23 and Secondary Hyperparathyroidism in a 58-Year-Old Man on Dialysis

Mineral disorders in chronic kidney disease are a lesson in how compensation can be both successful and harmful. As the kidneys fail, a sequence of hormonal responses keeps serum calcium and phosphate near normal for years. Each response, however, has side effects, and the final result is disease of bone and blood vessels. This case study examines a composite 58-year-old man on hemodialysis. It argues that his secondary hyperparathyroidism is the end of a chain of compensations that began with phosphate retention, that rising FGF23 and parathyroid hormone preserved his serum values at the cost of his skeleton and vessels, and that the parathyroid glands have now partly escaped feedback control.

Case Presentation

He has had type 2 diabetes for 20 years and has been on thrice-weekly hemodialysis for three years. He reports aching in both hips and his lower back for several months, constant itching and difficulty taking his phosphate binder with every meal. His laboratory results show calcium 8.4 mg/dL, phosphate 7.2 mg/dL, parathyroid hormone 980 pg/mL, alkaline phosphatase 310 U/L and 25-hydroxyvitamin D 18 ng/mL. A lateral abdominal radiograph shows calcification along the wall of the abdominal aorta.

Normal Regulation of Calcium and Phosphate

Serum calcium is held between about 8.5 and 10.2 mg/dL by parathyroid hormone and calcitriol, the active form of vitamin D (Hall & Hall, 2021). The chief cells of the parathyroid glands carry a calcium-sensing receptor. When ionized calcium falls, the receptor is less activated and parathyroid hormone is released. It releases calcium from bone, increases calcium reabsorption in the distal tubule, makes the proximal tubule let more phosphate escape into the urine and switches on renal 1-alpha-hydroxylase, which makes calcitriol. Calcitriol increases absorption of calcium and phosphate from the gut and, through vitamin D receptors on the parathyroid, suppresses parathyroid hormone, closing the loop.

Phosphate has its own regulator. Osteocytes in bone release fibroblast growth factor 23, known as FGF23, in response to phosphate load. Acting with its co-receptor klotho in the kidney, FGF23 increases phosphate excretion and suppresses calcitriol production. The system therefore has three hormones, each able to affect the others.

The First Failure and the First Compensation

As nephrons are lost, the kidneys filter less phosphate, and phosphate begins to accumulate. The earliest response is a rise in FGF23. In a large cohort of adults with chronic kidney disease, FGF23 was elevated more often than parathyroid hormone or phosphate at every level of kidney function, and it rose earliest as function declined (Isakova et al., 2011). By increasing phosphate excretion from each remaining nephron, FGF23 keeps serum phosphate normal in early disease.

The cost is calcitriol. FGF23 suppresses its production, and the damaged kidney also has less capacity to make it. Lower calcitriol reduces calcium absorption from the gut and removes one of the signals that normally restrain the parathyroid glands.

The Second Compensation: Rising Parathyroid Hormone

With less calcitriol, a tendency to lower calcium and continuing phosphate retention, the parathyroid glands increase hormone secretion. Parathyroid hormone restores calcium from bone and increases phosphate excretion from the remaining nephrons, keeping both serum values close to normal for years (Cunningham et al., 2011). This is the classic trade-off: normal blood values bought with a sustained high hormone level.

The cost falls first on bone. Continuously high parathyroid hormone drives rapid bone turnover, with increased resorption by osteoclasts and disorganized new bone formation. His elevated alkaline phosphatase reflects this high turnover, and his hip and back pain are its clinical expression. Over time, bone becomes weaker and fracture risk rises.

When Compensation Can No Longer Keep Up

Once kidney function is very low, as on dialysis, there are too few nephrons for FGF23 and parathyroid hormone to increase phosphate excretion enough. Phosphate rises despite both hormones being high, as his value of 7.2 mg/dL shows. Dialysis removes some phosphate but not as much as a normal diet contains, which is why binders taken with meals are essential and why missed doses matter.

The parathyroid glands also change. Prolonged stimulation causes the glands to enlarge, first by diffuse and then by nodular hyperplasia, and the enlarged glands have fewer calcium-sensing and vitamin D receptors (Cunningham et al., 2011). They respond less to the signals that should suppress them. His parathyroid hormone of 980 pg/mL, with a calcium that is only slightly low, reflects glands that are secreting more than the calcium level alone can explain. Feedback has partly failed at the gland itself.

Costs Beyond Bone

High phosphate combined with calcium promotes deposition of calcium phosphate in the walls of blood vessels, a process that is active rather than passive, with vascular smooth muscle cells taking on bone-like properties. His aortic calcification is visible evidence of this. Vascular calcification stiffens arteries, raises pulse pressure and contributes to the high cardiovascular risk seen in dialysis patients. His persistent itching is also common with high phosphate and parathyroid hormone in kidney failure, although its causes are multiple.

Treatment Logic

Treatment targets each link in the chain. Dietary phosphate restriction and binders taken with meals reduce the phosphate load that started the sequence; helping him take them consistently is the first step. His low 25-hydroxyvitamin D is replaced. Active vitamin D analogs replace missing calcitriol and suppress parathyroid hormone but can raise calcium and phosphate. Calcimimetics such as cinacalcet increase the sensitivity of the calcium-sensing receptor, lowering parathyroid hormone without raising calcium (Cunningham et al., 2011). When nodular glands no longer respond to medication, parathyroidectomy may be considered.

Implications for Practice

For a nurse practitioner caring for patients with chronic kidney disease before dialysis, the key insight is timing. The sequence begins years before serum values change, so normal calcium and phosphate do not mean the system is healthy. Monitoring parathyroid hormone and phosphate trends, supporting adherence to diet and binders and working with nephrology early can slow the chain before glands become nodular and vessels calcify.

Conclusion

This man's bone pain, itching and calcified aorta are the late costs of compensations that kept his blood values normal for years. Phosphate retention raised FGF23, which lowered calcitriol, which drove parathyroid hormone up, and each step preserved serum values while damaging bone and vessels. The glands have now enlarged and partly escaped feedback. Tracing the chain explains his findings and why treatment must address every link.

References

Cunningham, J., Locatelli, F., & Rodriguez, M. (2011). Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clinical Journal of the American Society of Nephrology, 6(4), 913-921. https://doi.org/10.2215/CJN.06040710

Hall, J. E., & Hall, M. E. (2021). Guyton and Hall textbook of medical physiology (14th ed.). Elsevier.

Isakova, T., Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Appleby, D., Nessel, L., Bellovich, K., Chen, J., Hamm, L., Gadegbeku, C., Horwitz, E., Townsend, R. R., Anderson, C. A. M., Lash, J. P., Hsu, C.-Y., Leonard, M. B., & Wolf, M. (2011). Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International, 79(12), 1370-1378. https://doi.org/10.1038/ki.2011.47